Clinical trial
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
NCT00234468 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00234468 |
|---|---|
| Title | Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC |
| Official title | A Phase III, Double-Blind, Randomised Study Comparing ZD1839 (IressaTM) Versus Placebo As Maintenance Therapy In Subjects With Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) After Combined Modality Therapy |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non Small Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | Iressa (Gefitinib) |
| Enrollment | 490 |
| Start date | Jan 1, 2004 |
| Completion | Aug 1, 2007 |
| First posted | Oct 7, 2005 |
| Last update posted | May 20, 2011 |
| Countries | Italy |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: